Amyloid Beta Exposed Neurons plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Neurons exposed to amyloid-beta (Aβ) plaques and oligomers undergo synaptic dysfunction, cellular stress, and eventually death in Alzheimer's disease (AD). Aβ is considered the initiating factor in the amyloid cascade hypothesis.
- α-secretase cleavage: Produces sAPPα and CTFα
- Product: Soluble fragment, non-amyloidogenic pathway
- Physiological role: Synaptic plasticity, neuroprotection
- β-secretase (BACE1): Produces sAPPβ and C99
- γ-secretase: Generates Aβ peptides (Aβ40, Aβ42)
- Aβ42: More aggregation-prone, primary pathogenic species
- Receptor interference: Aβ binds to numerous synaptic receptors
- LTP impairment: Long-term potentiation blocked
- ** glutamate toxicity**: Excitatory toxicity via NMDA receptors
- Synaptic loss: Early correlate of cognitive decline
- Oxidative stress: ROS production, lipid peroxidation
- ER stress: Unfolded protein response activation
- Mitochondrial dysfunction: Complex IV inhibition
- Calcium dysregulation: Homeostasis disruption
- Microglial activation: Chronic neuroinflammation
- Cytokine release: IL-1β, TNF-α, IL-6
- Complement activation: Synaptic pruning enhancement
- High metabolic demand: Active neurons more vulnerable
- Mitochondrial burden: High ROS production
- Calcium handling: Dysregulation triggers apoptosis
- Aging: Reduced proteostasis capacity
- Layer 2/3 cortical neurons: Early Aβ deposition
- CA1 pyramidal cells: Synaptic loss in stratum radiatum
- Parvalbumin interneurons: Network disruption
- Immunotherapies: Aduhelm, Lecanemab, Donanemab
- BACE inhibitors: Prevent Aβ production (challenging)
- Anti-aggregation agents: Prevent oligomer formation
- Passive immunization: Antibody delivery
Amyloid Beta Exposed Neurons plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Amyloid Beta Exposed Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Selkoe & Hardy, Amyloid cascade hypothesis (2024)
- Masters et al., Aβ biology in AD (2023)
- Walsh & Selkoe, Aβ oligomers (2020)
- Huang et al., BACE inhibitors in AD (2022)
- van Dyck, Lecanemab and Donanemab (2024)